Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of $163.43 billion. The enterprise value is $226.46 billion.
Important Dates
The next confirmed earnings date is Tuesday, October 29, 2024, before market open.
| Earnings Date | Oct 29, 2024 |
| Ex-Dividend Date | Nov 8, 2024 |
Share Statistics
Pfizer has 5.67 billion shares outstanding. The number of shares has decreased by -1.25% in one year.
| Shares Outstanding | 5.67B |
| Shares Change (YoY) | -1.25% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 67.42% |
| Float | 5.66B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.06 |
| PS Ratio | 2.96 |
| Forward PS | 2.54 |
| PB Ratio | 1.86 |
| P/FCF Ratio | 33.98 |
| PEG Ratio | 1.30 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 22.73, with an EV/FCF ratio of 47.08.
| EV / Earnings | n/a |
| EV / Sales | 4.11 |
| EV / EBITDA | 22.73 |
| EV / EBIT | 68.98 |
| EV / FCF | 47.08 |
Financial Position
The company has a current ratio of 0.86, with a Debt / Equity ratio of 0.79.
| Current Ratio | 0.86 |
| Quick Ratio | 0.51 |
| Debt / Equity | 0.79 |
| Debt / EBITDA | 6.21 |
| Debt / FCF | 14.52 |
| Interest Coverage | 1.11 |
Financial Efficiency
Return on equity (ROE) is -2.74% and return on invested capital (ROIC) is 1.27%.
| Return on Equity (ROE) | -2.74% |
| Return on Assets (ROA) | 0.94% |
| Return on Capital (ROIC) | 1.27% |
| Revenue Per Employee | $626,886 |
| Profits Per Employee | -$29,489 |
| Employee Count | 88,000 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 2.02 |
Taxes
| Income Tax | -1.60B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.91% in the last 52 weeks. The beta is 0.62, so Pfizer's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -5.91% |
| 50-Day Moving Average | 29.07 |
| 200-Day Moving Average | 28.21 |
| Relative Strength Index (RSI) | 45.57 |
| Average Volume (20 Days) | 29,659,456 |
Short Selling Information
The latest short interest is 67.62 million, so 1.19% of the outstanding shares have been sold short.
| Short Interest | 67.62M |
| Short Previous Month | 65.38M |
| Short % of Shares Out | 1.19% |
| Short % of Float | 1.19% |
| Short Ratio (days to cover) | 2.23 |
Income Statement
In the last 12 months, Pfizer had revenue of $55.17 billion and -$2.60 billion in losses. Loss per share was -$0.47.
| Revenue | 55.17B |
| Gross Profit | 33.19B |
| Operating Income | 3.28B |
| Pretax Income | -4.20B |
| Net Income | -2.60B |
| EBITDA | 9.96B |
| EBIT | 3.28B |
| Loss Per Share | -$0.47 |
Full Income StatementBalance Sheet
The company has $7.10 billion in cash and $69.86 billion in debt, giving a net cash position of -$62.76 billion or -$11.07 per share.
| Cash & Cash Equivalents | 7.10B |
| Total Debt | 69.86B |
| Net Cash | -62.76B |
| Net Cash Per Share | -$11.07 |
| Equity (Book Value) | 87.98B |
| Book Value Per Share | 15.48 |
| Working Capital | -5.99B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $8.01 billion and capital expenditures -$3.20 billion, giving a free cash flow of $4.81 billion.
| Operating Cash Flow | 8.01B |
| Capital Expenditures | -3.20B |
| Free Cash Flow | 4.81B |
| FCF Per Share | $0.85 |
Full Cash Flow StatementMargins
Gross margin is 60.16%, with operating and profit margins of 5.95% and -4.70%.
| Gross Margin | 60.16% |
| Operating Margin | 5.95% |
| Pretax Margin | -7.55% |
| Profit Margin | -4.70% |
| EBITDA Margin | 18.06% |
| EBIT Margin | 5.95% |
| FCF Margin | 8.64% |
Dividends & Yields
This stock pays an annual dividend of $1.68, which amounts to a dividend yield of 5.83%.
| Dividend Per Share | $1.68 |
| Dividend Yield | 5.83% |
| Dividend Growth (YoY) | 2.44% |
| Years of Dividend Growth | 13 |
| Payout Ratio | n/a |
| Buyback Yield | 1.25% |
| Shareholder Yield | 7.07% |
| Earnings Yield | -1.59% |
| FCF Yield | 2.94% |
Dividend DetailsAnalyst Forecast
The average price target for Pfizer is $33.91, which is 17.58% higher than the current price. The consensus rating is "Buy".
| Price Target | $33.91 |
| Price Target Difference | 17.58% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 1.48% |
| EPS Growth Forecast (5Y) | 50.93% |
Stock ForecastsStock Splits
The last stock split was on July 1, 1999. It was a forward split with a ratio of 3:1.
| Last Split Date | Jul 1, 1999 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Pfizer has an Altman Z-Score of 1.83 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.83 |
| Piotroski F-Score | 4 |